A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

The Food and Drug Administration on Tuesday approved the experimental Alzheimer's drug donanemab, which slowed the early stages of the fatal mind-robbing disease in studies. The approval comes ...

Eli Lilly and Company. "Kisunla continues to demonstrate very meaningful results for people with early symptomatic Alzheimer's disease and can now help to improve the standard of care for people ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Is Eli Lilly a good stock to buy on the dip ... Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...